

Clinics, 301 Business Loop 70 West,
Suite 208, Columbia, MO 65203, 573-
882-1273.

Toxicology Testing Service, Inc., 5426 N.W.
79th Ave., Miami, FL 33166, 305-593-
2260.

US Army Forensic Toxicology Drug Testing
Laboratory, 2490 Wilson St., Fort George
G. Meade, MD 20755-5235, 301-677-
7085.

The following laboratory's
certification was suspended on
November 14, 2005, with an effective
date of November 15, 2005, and then
revoked on February 8, 2006:

Sciteck Clinical Laboratories, Inc., 317
Rutledge Road, Fletcher, NC 28732, 828-
650-0409.

* The Standards Council of Canada (SCC)
voted to end its Laboratory Accreditation
Program for Substance Abuse (LAPSA)
effective May 12, 1998. Laboratories certified
through that program were accredited to
conduct forensic urine drug testing as
required by U.S. Department of
Transportation (DOT) regulations. As of that
date, the certification of those accredited
Canadian laboratories will continue under
DOT authority. The responsibility for
conducting quarterly performance testing
plus periodic on-site inspections of those
LAPSA-accredited laboratories was
transferred to the U.S. HHS, with the HHS'
NLCP contractor continuing to have an active
role in the performance testing and
laboratory inspection processes. Other
Canadian laboratories wishing to be
considered for the NLCP may apply directly
to the NLCP contractor just as U.S.
laboratories do.

Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (**Federal
Register**, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the **Federal
Register** on April 13, 2004 (69 FR
19644). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHS-
certified laboratories and participate in
the NLCP certification maintenance
program.

Anna Marsh,
Director, Office Program Services, SAMHSA.
[FR Doc. E6-7316 Filed 5-11-06; 8:45 am]

BILLING CODE 4160-20-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-5045-N-19]

Federal Property Suitable as Facilities To Assist the Homeless

AGENCY: Office of the Assistant
Secretary for Community Planning and
Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies
unutilized, underutilized, excess, and
surplus Federal property reviewed by
HUD for suitability for possible use to
assist the homeless.

DATES: *Effective Date:* May 12, 2006.

FOR FURTHER INFORMATION CONTACT:
Kathy Ezzell, Department of Housing
and Urban Development, Room 7262,
451 Seventh Street SW., Washington,
DC 20410; telephone (202) 708-1234;
TTY number for the hearing- and
speech-impaired (202) 708-2565, (these
telephone numbers are not toll-free), or
call the toll-free title V information line
at 1-800-927-7588.

SUPPLEMENTARY INFORMATION: In
accordance with the December 12, 1988
court order in *National Coalition for the
Homeless v. Veterans Administration*,
No. 88-2503-OG (D.D.C.), HUD
publishes a Notice, on a weekly basis,
identifying unutilized, underutilized,
excess and surplus Federal buildings
and real property that HUD has
reviewed for suitability for use to assist
the homeless. Today's Notice is for the
purpose of announcing that no
additional properties have been
determined suitable or unsuitable this
week.

Dated: May 4, 2006.

Mark R. Johnston,
*Acting Deputy Assistant Secretary for Special
Needs.*

[FR Doc. 06-4318 Filed 5-11-06; 8:45am]

BILLING CODE 4210-67-M

INTERNATIONAL TRADE COMMISSION

[Inv. No. 337-TA-568]

In the Matter of Certain Products and Pharmaceutical Compositions Containing Recombinant Human Erythropoietin; Notice of Investigation

AGENCY: U.S. International Trade
Commission.

ACTION: Institution of investigation
pursuant to 19 U.S.C. 1337.

SUMMARY: Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
April 11, 2006, under section 337 of the
Tariff Act of 1930, as amended, 19
U.S.C. 1337, on behalf of Amgen Inc. of
Thousand Oaks, California. Amgen filed
an amended complaint and a
supplement on April 27, 2006. The
amended complaint alleges violations of
section 337 in the importation into the
United States of certain products and
pharmaceutical compositions

containing recombinant human
erythropoietin by reason of infringement
of claims 1 and 2 of U.S. Patent No.
5,441,868, claims 3, 4, 5, and 11 of U.S.
Patent No. 5,547,933, claims 4-9 of U.S.
Patent No. 5,618,698, claims 4 and 6 of
U.S. Patent No. 5,621,080, claim 7 of
U.S. Patent No. 5,756,349, and claim 1
of U.S. Patent No. 5,955,422. The
complaint further alleges that an
industry in the United States exists as
required by subsection (a)(2) of section
337.

The complainant requests that the
Commission institute an investigation
and, after the investigation, issue a
permanent exclusion order and
permanent cease and desist orders.

ADDRESSES: The amended complaint,
except for any confidential information
contained therein, is available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street, SW., Room 112, Washington, DC
20436, telephone 202-205-2000.
Hearing impaired individuals are
advised that information on this matter
can be obtained by contacting the
Commission's TDD terminal on 202-
205-1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202-205-2000.
General information concerning the
Commission may also be obtained by
accessing its Internet server at <http://www.usitc.gov>. The public record for
this investigation may be viewed on the
Commission's electronic docket (EDIS)
at <http://edis.usitc.gov>.

FOR FURTHER INFORMATION CONTACT:
Anne Goalwin, Office of Unfair Import
Investigations, U.S. International Trade
Commission, telephone (202) 205-2574.

Authority: The authority for institution of
this investigation is contained in section 337
of the Tariff Act of 1930, as amended, and
in section 210.10 of the Commission's Rules
of Practice and Procedure, 19 CFR 210.10
(2005).

Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
May 8, 2006, *ordered that*—

(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products and
pharmaceutical compositions
containing recombinant human

erythropoietin by reason of infringement of one or more of claims 1 and 2 of U.S. Patent No. 5,441,868, claims 3, 4, 5, and 11 of U.S. Patent No. 5,547,933, claims 4–9 of U.S. Patent No. 5,618,698, claims 4 and 6 of U.S. Patent No. 5,621,080, claim 7 of U.S. Patent No. 5,756,349, and claim 1 of U.S. Patent No. 5,955,422, and whether an industry in the United States exists as required by subsection (a)(2) of section 337.

(2) In instituting this investigation, the Commission is mindful of the provision of 35 U.S.C. 271(e), which states that “[i]t shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into the United States a patented invention * * * solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs * * *.” Accordingly, the Commission directs the presiding administrative law judge to consider at an early date any motions for summary determination based upon 35 U.S.C. 271(e). Any decision granting or denying such motions should be issued in the form of an initial determination (ID) under Rule 210.42(c), 19 CFR 210.42(c). The ID will become the Commission’s final determination 45 days after the date of service of the ID unless the Commission determines to review the ID. Any such review will be conducted in accordance with Commission Rules 210.43, 210.44 and 210.45, 19 CFR 210.43, 210.44, and 210.45.

(3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served:

(a) The complainant is—
Amgen Inc., One Amgen Center Drive,
Thousand Oaks, California 91320.

(b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served:
Roche Holding Ltd., Grenzacherstrasse
124, CH–4070, Basel, Switzerland.
F. Hoffmann-La Roche, Ltd.,
Grenzacherstrasse 124, CH–4070,
Basel, Switzerland.
Roche Diagnostics GmbH, Sandhofer
Strasse 116, D–68305, Mannheim,
Germany.
Hoffmann La Roche, Inc., 340 Kingsland
Street, Nutley, New Jersey 07110.

(c) The Commission investigative attorney, party to this investigation, is Anne Goalwin, Esq., Office of Unfair Import Investigations, U.S. International Trade Commission, 500 E Street, SW., Suite 401, Washington, DC 20436; and

(4) For the investigation so instituted, the Honorable Paul J. Luckern is designated as the presiding administrative law judge.

Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(d) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown.

Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondents, to find the facts to be as alleged in the complaint and this notice and to enter a final determination containing such findings, and may result in the issuance of a limited exclusion order or cease and desist order or both directed against the respondent.

Issued: May 9, 2006.

By order of the Commission.

Marilyn R. Abbott,

Secretary to the Commission.

[FR Doc. E6–7307 Filed 5–11–06; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Bureau of Alcohol, Tobacco, Firearms and Explosives

Agency Information Collection Activities: Proposed Collection; Comments Requested

ACTION: 30-Day notice of information collection under review: Federal firearms licensee firearms inventory theft/loss report.

The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and

affected agencies. This proposed information collection was previously published in the **Federal Register** volume 71, number 48, pages 12713–12714 on March 13, 2006, allowing for a 60 day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until June 12, 2006. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to The Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB VIA FACSIMILE TO (202) 395–5806.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Overview of This Information Collection

(1) *Type of Information Collection:* Extension of a currently approved collection.

(2) *Title of the Form/Collection:* Federal Firearms Licensee Firearms Inventory Theft/Loss Report.

(3) *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* Form Number: ATF F 3310.11. Bureau of Alcohol, Tobacco, Firearms and Explosives.

(4) *Affected public who will be asked or required to respond, as well as a brief*